Global X Robo Global Robotics & Automation ETF vs BIO-TECHNE Corp — how do they compare? Global X Robo Global Robotics & Automation ETF trades at $84.05, while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: BIO-TECHNE Corp pays a 0.44% dividend while Global X Robo Global Robotics & Automation ETF pays none, and BIO-TECHNE Corp is trading nearer its 52-week high, Global X Robo Global Robotics & Automation ETF nearer its low. Which is the better fit depends on your goals.
| ROBO | TECH | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $90.34 | $72.29 |
52-Week Low | $62.34 | $43.31 |
Market Cap | — | $11.24B |
Enterprise Value | — | $11.32B |
Dividend Yield | — | 0.44% |
Signals from Pluang's Aura AI — not financial advice
ROBO trades at $84.44, up 1.65% with bullish momentum from moving averages and a neutral oscillator stance. Recent news highlights robotics sector strength, with thematic ETFs gaining attention for AI infrastructure exposure. The stock faces resistance near $85, with support at $84.
Outlook remains positive due to AI-driven demand, but overbought RSI signals caution. Risks include cyclical exposure and valuation concerns. Analysts favor long-term growth, yet near-term volatility may test recent gains.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Trailing returns across standard periods
ROBO is a thematic ETF that tracks the global robotics and automation industry. It provides diversified exposure to companies leading in industrial robotics, 3D printing, and surgical systems, with holdings like Intuitive Surgical and Zebra Technologies.
Read more on ROBO →Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →